Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Instagram Outage Disrupts Thousands of U.S. Users 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2017 -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at the 2017 Wedbush PacGrow Healthcare Conference taking place August 15 to 16, 2017 at the Le Parker Meridien hotel in New York, NY. Achaogen’s management will present at 10:55 a.m. Eastern Daylight Time on Tuesday, August 15th, 2017.
A link to the live audio webcast of the presentation, and a replay of the presentation for 30 days following the conference, will be available in the "Investors" section of Achaogen’s website, www.achaogen.com.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. The Company’s second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination. Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections and additional disease areas. All product candidates are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Achaogen Contact: David Arrington Vice President, Investor Relations and Corporate Communications 650.440.5856 [email protected]
